Anthera Pharmaceuticals, Inc.

NASDAQ: ANTH
$0.04
+$0.00 (+0.0%)
Closing price August 10, 2020
Anthera Pharmaceuticals, Orexigen Therapuetics, VEON, and New Gold all posted new 52-week lows Monday.
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) saw its shares get absolutely crushed in Monday’s session following missed results in a late-stage study. Specifically, the company said that Sollpura...
The top analyst upgrades, downgrades and other research calls from Wednesday include Capital One, Domino's, Home Depot, Mosaic, Regenron, Six Flags, U.S. Steel and Walmart.
With the passage of tax reform looking almost certain, and with companies continuing to prove that all-time highs in the market will not hurt spending cash on share buybacks, the continuation of...
Guess, Anthera Pharmaceuticals, Walter Investment Managemen, and Rentech all posted new 52-week lows Thursday.
Valeant, J.C. Penney, Frontier Communications, and Anthera Pharmaceuticals all posted new 52-week lows Tuesday.
December 30, 2016: Here are four stocks trading with relatively heavy volume among 66 equities making new 52-week lows in Friday’s session. On the NYSE, decliners led advancers by about 3 to 2...
Thursday’s top analyst upgrades, downgrades and initiations include Biogen, Comerica, Deere, NVIDIA and Twenty-First Century Fox.
December 28, 2016: Here are four stocks trading with relatively heavy volume among 59 equities making new 52-week lows in Wednesday’s session. On the NYSE, decliners led advancers by nearly 3...
The U.S. presidential election is now over and markets have seemingly recovered to just below their highs but there are still some laggards.
Shares of Anthera Pharmaceuticals lost roughly one-third of their value on Thursday after the company gave an update on its late-stage Lupus clinical trial.
24/7 Wall St. has collected several big FDA decisions and mid-stage to late-stage trials that should be announced in October.
24/7 Wall St. has collected several big FDA decisions and mid-to-late-stage trials that should be coming up in October. These catalyst events can make or break these companies.
On Tuesday, a few biotech companies made substantial runs, either up and down, due to the results of FDA approvals, failed or passed trials and even earnings results.
The top analyst upgrades, downgrades and initiations seen on Friday, February 19, include Applied Materials, Duke Energy, Entergy, Salesforce,com and SunEdison.